C3i Center Inc
C3i Center Inc (C3i) is a CDMO with full in-house services in cell and virus manufacturing from process development to commercialization. C3i is Health Canada, FDA and EMA compliant producing for the US, Canada and EU with first commercialized product in 2024 for the EU market. C3i performs in-house all Qc for safety and product release testing as well as immune monitoring testing of patients who have received cell therapies. Additional services include clinical trial CRO services, access to KOLs, protocol development and key patient access. C3i has expertise in autologous and allogenic therapies, Crispr editing, viral and non-viral transduction.